Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Peposertib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 21 May 2024 Status changed from suspended to recruiting.
- 01 May 2024 Status changed from recruiting to suspended due to a DLT assessment specified in protocol.
- 06 Apr 2023 Planned End Date changed from 24 Jul 2023 to 31 Jul 2025.